We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+45.97%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
+$1.91B
Cap. Flow
+$58.2M
Cap. Flow %
0.82%
Top 10 Hldgs %
40.22%
Holding
232
New
17
Increased
84
Reduced
52
Closed
24

Top Buys

Rank Stock Value
1
GBIO
Generation Bio
GBIO
+$32.1M
2
SYK icon
Stryker
SYK
+$27.9M
3
PODD icon
Insulet
PODD
+$24.7M
4
BMY icon
Bristol-Myers Squibb
BMY
+$24.3M
5
DVA icon
DaVita
DVA
+$23.4M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$78.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$34.5M
3
ILMN icon
Illumina
ILMN
+$34.1M
4
MRNA icon
Moderna
MRNA
+$33.1M
5
AKCA
Akcea Therapeutics Inc
AKCA
+$26.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.05%
2 Industrials 0.58%
3 Technology 0.42%
4 Communication Services 0.29%
5 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLX icon
176
Clorox
CLX
$11.6B
$439K 0.01%
2,000
-800
-29% -$160K
VRSN icon
177
VeriSign
VRSN
$25.3B
$434K 0.01%
2,100
– –
IPGP icon
178
IPG Photonics
IPGP
$3.89B
$433K 0.01%
2,700
-800
-23% -$114K
ENTG icon
179
Entegris
ENTG
$19.7B
$431K 0.01%
7,300
-3,000
-29% -$167K
BR icon
180
Broadridge
BR
$17.2B
$429K 0.01%
3,400
– –
FAST icon
181
Fastenal
FAST
$54B
$428K 0.01%
20,000
-18,598
-48% -$356K
EL icon
182
Estee Lauder
EL
$29B
$424K 0.01%
2,248
– –
VRSK icon
183
Verisk Analytics
VRSK
$26.4B
$424K 0.01%
2,489
– –
CTLT
184
DELISTED
CATALENT, INC.
CTLT
$418K 0.01%
5,700
-41,400
-88% -$2.81M
XLNX
185
DELISTED
Xilinx Inc
XLNX
$413K 0.01%
4,200
– –
MKTX icon
186
MarketAxess Holdings
MKTX
$4.15B
$412K 0.01%
822
-500
-38% -$233K
IQV icon
187
IQVIA
IQV
$34.7B
$411K 0.01%
2,900
+1,000
+53% +$136K
PAYX icon
188
Paychex
PAYX
$40.4B
$409K 0.01%
5,400
– –
FTNT icon
189
Fortinet
FTNT
$112B
$398K 0.01%
+14,500
New +$364K
MSCI icon
190
MSCI
MSCI
$40B
$396K 0.01%
1,186
-600
-34% -$194K
TW icon
191
Tradeweb Markets
TW
$21.3B
$395K 0.01%
+6,800
New +$392K
IBKR icon
192
Interactive Brokers
IBKR
$40.9B
$393K 0.01%
37,600
– –
DPZ icon
193
Domino's
DPZ
$11B
$369K 0.01%
1,000
-900
-47% -$332K
MKL icon
194
Markel Group
MKL
$25B
$369K 0.01%
400
– –
ST icon
195
Sensata Technologies
ST
$6.65B
$369K 0.01%
9,900
– –
WAB icon
196
Wabtec
WAB
$51.1B
$368K 0.01%
6,400
– –
STZ icon
197
Constellation Brands
STZ
$22.2B
$360K 0.01%
2,059
– –
AVNT icon
198
Avient
AVNT
$3.45B
$357K 0.01%
13,600
– –
AXP icon
199
American Express
AXP
$223B
$343K ﹤0.01%
3,600
– –
TCOM icon
200
Trip.com Group
TCOM
$27.5B
$340K ﹤0.01%
13,100
– –
6 7
8
9 10

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q2 2020 Portfolio in Review

As of Q2 2020, Bellevue Group held 232 positions worth $7.07B, up 37% from $5.16B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group's Q2 2020 filing shows 17 new, 84 increased, 52 reduced and 24 closed positions. Its largest new stake was Generation Bio: 144,000 shares worth $30.2M. The largest sale was Vertex Pharmaceuticals, an estimated $78.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2020 buy was Generation Bio: 144,000 shares worth $30.2M.
  • Bellevue Group added most to Stryker in Q2 2020, an estimated $27.9M increase.
  • Bellevue Group's biggest Q2 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $78.8M.
  • Bellevue Group fully exited QuidelOrtho in Q2 2020, selling an estimated $11.1M.
  • Bellevue Group's ten largest holdings make up 40% of its $7.07B portfolio in Q2 2020.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2020.
  • Bellevue Group's portfolio value rose 37% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2020, filed 13 Aug 2020.